A plate can finish quickly and still leave the experiment short of cells. For screening flow cytometry, count throughput in wells that yield enough valid events from the population being studied. Bright beads, abundant lymphocytes and rare responding cells place very different demands on sampling. Each needs its own sampling depth before acquisition time becomes useful.
This comparison covers Sartorius iQue 5, Beckman Coulter CytoFLEX S with its specified plate loader, and Thermo Fisher Attune NxT with CytKick or CytKick Max. Attune CytPix is discussed where its imaging capability changes interpretation. These are representative screening and shared-lab configurations, not a complete cytometer catalog. The emphasis is on sample recovery, event statistics, panel performance, carryover and the work between loading a plate and accepting its results.
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Choose the biological population before the acquisition speed. MEASUREMENT OBJECTIVE | \nA well may contain live target cells, dead cells, debris, effector cells, aggregates and assay beads. Only some recorded events support a particular endpoint, and the relevant fraction can change with treatment. | \nA fixed total-event target gives inconsistent precision if a compound depletes the population of interest. A fixed acquisition time can give inconsistent counts when cell concentration varies. | \nDefine the necessary live-singlet or other target population before choosing stop rules. Inspect the count reaching the final gate in every well. Treat insufficient-event wells explicitly rather than letting a smooth concentration-response fit hide their uncertainty. Proposed assay-design and data-review rules. | \n
Fast sampling and deep sampling answer different needs. WORKFLOW FIT | \niQue 5 emphasizes microvolume plate sampling. CytoFLEX S offers a configurable analyzer with an optional 96-well loader. Attune configurations combine acoustic focusing with selectable sample flow and autosampler options. | \nMaximum event rate, plate cycle time and volume recovered are different quantities. A short advertised cycle may sample less liquid than the workflow beside it in the comparison. | \nChoose the configuration around required events per well, acceptable carryover and the panel's separation. Measure a representative plate from loading through analysis. Require the same biological acceptance criteria across candidates even when their acquisition methods differ. Sources: F1, F2, F4. Manufacturer positioning and proposed comparison basis. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
iQue 5 supports 96 and 384 well screening. IQUE CONFIGURATION | \nSartorius lists three- or four-laser iQue 5 configurations with 21 or 27 detection channels, a 1 µL minimum aspiration and minimum sampling times below five minutes for 96 wells and twenty minutes for 384 wells. | \nThat aspiration minimum leaves useful cell yield and required starting volume to be established for the method. Detection-channel totals should not be equated automatically with independently usable fluorescence markers. | \nConsider iQue for repeated microplate screening where integrated acquisition and plate analysis are valuable. Bring dilute and heterogeneous samples to the demonstration. Confirm the event yield, rejected wells and any additional sampling needed to meet the assay's count requirement. Sources: F1. Published minima, not a matched-sample benchmark. | \n
The named CytoFLEX loader is a 96 well configuration. CYTOFLEX CONFIGURATION | \nBeckman's CytoFLEX S page lists an optional 96-well sample loader. The C16574 loader supports standard and deep-well 96-well plates. Available optical configurations vary within the S family. | \nDo not infer 384-well acquisition from another CytoFLEX product, or confuse a sorter's plate-deposition capability with an analyzer's plate sampling. Sample reformatting would add a separate workflow step. | \nThis can be a practical shared-lab candidate when its exact panel and 96-well workflow meet demand. If 384-well acquisition is essential, require written confirmation of a compatible alternative configuration rather than treating the family name as evidence. Sources: F2, F3. Configuration-specific compatibility check. | \n
Attune timing claims include a defined sampled volume. ATTUNE CONFIGURATION | \nThermo's NxT specification sheet lists CytKick Max Boost-mode times of 22 minutes for 96 wells and 88 minutes for 384 wells, with one mix, one rinse and analysis of 20 µL at 1,000 µL/min. | \nThese conditions differ from a minimum microvolume-sampling claim. They cannot establish a several-fold speed ranking against another instrument without matching event recovery and other acceptance criteria. | \nUse the published conditions as a reproducible starting point for a demonstration. Test the volume and rinse settings your cells require. Include setup, mixing, failed-well repeats and data review when calculating the practical number of plates per working day. Sources: F4. PDF p 5; conditions retained from the manufacturer table. | \n
Starting well volume can be much larger than the analyzed volume. SAMPLE BUDGET | \nAutosampler methods need accessible liquid for probe positioning, mixing and collection. Minimum aspiration, analyzed volume and residual dead volume describe different stages of the operation. | \nFlat, U- and V-bottom wells have different liquid geometry. A plate that fits mechanically may still leave an unacceptable fraction of a scarce cell sample inaccessible under the chosen method. | \nMeasure cell recovery from the intended plate at the intended fill volume. Use counts before and after sampling where feasible. Ask how repeated sampling and mixing affect residual volume, and include that loss in the number of cells that must be prepared. Sources: F5. Proposed volume and recovery qualification. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
High sample flow cannot abolish coincidence. ACOUSTIC FOCUSING | \nThermo describes acoustic focusing and sample flow up to 1,000 µL/min for Attune. Its capabilities guide qualifies a stated acquisition rate using a 10% coincidence condition based on Poisson statistics. | \nGood focusing does not guarantee that every arriving cell becomes a separately recorded event. Increasing concentration or delivery rate can change event losses and the reliability of apparent counts. | \nChallenge the same sample over a dilution series and sensible flow settings. Inspect event-rate linearity, abort information, pulse shape and population recovery. Select a setting that preserves the endpoint rather than automatically using the highest available flow rate. Sources: F6. Manufacturer principle and rate qualification; proposed test. | \n
More colors can make the decisive marker harder to resolve. PANEL DESIGN | \nNguyen and colleagues describe spillover spreading and a matrix for quantifying it. Correcting the mean contribution of fluorescence in another channel does not eliminate the propagated measurement spread. | \nBright coexpressed markers can broaden the distribution in a channel used for a dim biological response. Raw detector counts or a long fluorochrome list do not establish the panel's usable resolution. | \nCompare the actual panel on representative treated and untreated cells. Use appropriate single-stain and fluorescence-minus-one controls. Give important dim markers favorable fluorochrome and detector combinations, and inspect spreading when evaluating apparently similar configurations. Sources: F8. Primary-research principle; proposed panel comparison. | \n
Imaging can explain events that scatter gates leave ambiguous. ATTUNE CYTPIX OPTION | \nThermo's capabilities guide distinguishes Attune CytPix, which records brightfield images, from NxT, which does not provide that imaging feature. Images add information about the events passing through the instrument. | \nImage capture has its own throughput and data burden. It should not be assumed to provide an image for every fluorescence event under every acquisition setting, nor to replace a confocal cellular assay. | \nConsider CytPix when aggregates, cell morphology or unusual treated populations repeatedly complicate interpretation. Demonstrate how images are linked to gates and reviewed at screening scale. Keep any CytPix quotation and performance claims separate from the NxT configuration compared here. Sources: F6. Manufacturer distinction and application recommendation. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Cells and secreted proteins can be measured in a shared sample. MULTIPLEX BIOLOGY | \nSartorius describes iQue assays combining cell phenotyping with bead-based secreted-protein detection in the same well. This can connect cellular state with an extracellular response within a common sample workflow. | \nThe bead population needs sufficient events and its own calibration. Secreted protein remains a well-level measurement; it cannot be assigned to an individual cell from shared-well detection alone. The reagents must also remain compatible. | \nEvaluate whether the combined assay reduces handling without compromising either endpoint. Track cell and bead counts independently. Confirm the dynamic range and dilution requirement for the secreted analyte rather than assuming the cell assay's preferred conditions serve both measurements. Sources: F7. Platform application; interpretation and proposed controls. | \n
Rare populations impose a count requirement. SAMPLING STATISTICS | \nFor a constructed population occurring at 0.1%, collecting 10,000 independent eligible cells gives an expected ten target events. At low frequency, the approximate relative counting uncertainty is 1/√k, where k is the expected target count. | \nTen expected target events imply about 32% relative counting uncertainty; 100 imply about 10%. Reaching 100 at 0.1% requires roughly 100,000 eligible cells. These are sampling estimates, not total assay CVs. | \nWork backward from the target precision to the eligible cell count and sample volume. Include losses from viability and singlet gates. Use statistical intervals for sparse observed counts, and avoid interpreting a handful of events as a finely measured potency shift. Constructed binomial/Poisson approximation; no instrument measurement. | \n
The acquisition rule can interact with compound biology. CYTOTOXIC AND CYTOSTATIC EFFECTS | \nA treatment may reduce cell number, alter scatter or change marker expression. A gate or stopping rule chosen on healthy controls can therefore affect treated wells differently. | \nExtending collection until every well supplies a fixed number of survivors can change the sampled volume and the elapsed time. Keeping a fixed duration can instead leave sparse wells with much poorer precision. | \nRetain sampled volume, collection time and gate counts alongside percentages. Decide whether the endpoint is frequency, intensity, absolute count or a combination. Validate the count method independently when cell number itself is part of the biological conclusion. Proposed interpretation and acquisition controls. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Small carryover can matter greatly in a rare-cell assay. SAMPLE SEQUENCE | \nCarryover is residual material from an earlier sample entering a later one. Its consequence depends on the concentration and identity of the preceding sample, not simply on a reassuring average percentage. | \nIn a constructed case, a recipient sample has 10,000 cells including ten true target cells. Adding ten target cells from the previous sample raises the observed target fraction from 0.10% to about 0.20%. | \nTest high–blank–low sequences with a distinguishable cell or bead population and the intended rinse program. Inspect blanks immediately after the strongest samples. Adequate cleaning and sampling design prevent a problem that arithmetic subtraction cannot fully repair: the contaminating events have already entered the data. Constructed contamination example and proposed test. | \n
Cells continue changing while a plate waits. SETTLING AND TEMPERATURE | \nThe CytKick manual describes configurable sample mixing and wash operations. Those operations contribute to cycle time and determine the physical treatment of each well before acquisition. | \nSettling, clumping and biological drift can make early and late wells differ. Stable temperature helps control one variable, but the suitable temperature depends on the live-cell or fixed-cell assay rather than a universal room-temperature rule. | \nCompare early and late control wells and retain acquisition order. Qualify mixing for both uniform sampling and cell health. Use validated holding conditions and limits on queue time; record whether a cooling accessory controls sample temperature or merely slows warming. Sources: F5. Manual-supported operations and proposed queue qualification. | \n
Plate throughput can move the bottleneck into analysis. DATA WORKLOAD | \nA screen produces many population distributions, gate decisions and quality exceptions. The analysis must preserve plate identity, controls, treatment metadata and the relationship between raw events and reported results. | \nAutomated gates can fail systematically on a treatment-shifted population. Manual review of every plot can become the dominant labor cost, while silent exclusion of difficult wells can bias the hit list. | \nDemonstrate a plate with deliberately difficult samples. Measure the time to an auditable result, including failed-well review. Require access to raw event files, analysis settings and the reason each well was accepted or rejected. Proposed software acceptance test. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
iQue deserves a place on a screening-focused shortlist. REPEATED PLATE WORK | \nThe iQue platform combines plate acquisition with Forecyt analysis and screening-oriented assay workflows. Its microvolume approach is a practical candidate when samples contain enough eligible events at the available concentration. | \nThe screening advantage must survive the assay's required sampling depth and controls. A very dilute sample or rare endpoint may need more acquisition than a minimum-time specification represents. | \nTest the full screen recipe, from layout import through concentration-response analysis. Include cell loss, interference and missing-well cases. Favor the integrated workflow when it reduces hands-on review while preserving traceability and the required biological precision. Sources: F1. Configuration-based recommendation, not an independent speed ranking. | \n
CytoFLEX S can suit a shared 96 well laboratory. FLEXIBLE ANALYZER USE | \nCytoFLEX S offers multiple laser/filter configurations and CytExpert acquisition and analysis. Beckman describes an API for external control and integration with its liquid-handling platforms. | \nFlexibility can be valuable when users bring different panels, but method changeover, training and maintenance still consume time. Optional automation and optical upgrades must be included in the proposed configuration. | \nAssess it with the core lab's recurring panels and a realistic schedule of tube and plate work. Make 96-well throughput a measured acceptance criterion. Select it for a demonstrated workload fit rather than assuming a configurable analyzer automatically behaves like a dedicated screening workcell. Sources: F2. Manufacturer features and workflow recommendation. | \n
Attune merits testing when useful sampling volume is a priority. VOLUME AND EVENT YIELD | \nAttune's acoustic-focusing approach provides selectable high sample flow, and its autosampler methods specify analyzed volume and mixing. This gives a concrete basis for a demonstration with relatively dilute samples. | \nMore sampled liquid is useful only while coincidence, background, carryover and population recovery remain acceptable. Additional sample volume also increases the number of cells and reagents the assay must supply. | \nCompare accepted events per microliter and per minute over the relevant concentration range. For scarce samples, include accessible volume and residual loss. Use the resulting data to choose an acquisition method before comparing end-to-end plate productivity. Sources: F4, F6. Mechanistic and workflow inference; proposed measurement. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Use one challenge plate to compare the complete methods. DEMONSTRATION PLAN | \nInclude abundant and rare target populations, a dilution series, a bright interfering marker, aggregates and high–blank–low sequences. Distribute stable controls so acquisition-order effects can be detected. | \nKeep biological preparation comparable while allowing each supplier to optimize a documented method. Artificially forcing identical flow settings can disadvantage a different sampling architecture without creating a fair scientific comparison. | \nCompare final-gate counts, dim-population separation, carryover, rejected events, missed wells and review time. Set acceptable errors before the demonstration. Repeat on another day to test whether the method can be handed to the operators who will actually use it. Proposed matched-objective benchmark. | \n
Cost the usable results and the labor behind them. PURCHASING DECISION | \nThe relevant quote includes the cytometer configuration, loader, software seats, integration, QC materials, cleaning supplies, service and training. A screening workflow may also need sample preparation automation and protected plate storage. | \nNeither acquisition specifications nor list-price fragments establish total cost per accepted well. Instrument downtime and the time spent resolving bad gates can exceed the apparent saving from a faster plate cycle. | \nBuild the comparison around a stated annual workload and a defined endpoint. Ask suppliers to provide the configuration used in the demonstration and the support needed to maintain it. Record which future assays the proposed configuration can support, and which would require another purchase. Procurement framework; no price or service-performance ranking claimed. | \n
Manufacturer specifications describe the named product and configuration; they are not independent all-vendor benchmarks. Row-level source IDs link to the references below. Calculations and practical interpretations are identified separately. No physical comparison or procurement quotation is represented by these tables.
F3 CytoFLEX plate loader C16574
F4 Attune NxT specification sheet
F5 CytKick and CytKick MAX user guide
F6 Thermo flow cytometry capabilities guide
F7 iQue cells and secreted proteins
", "body_text": "A plate can finish quickly and still leave the experiment short of cells. For screening flow cytometry, count throughput in wells that yield enough valid events from the population being studied. Bright beads, abundant lymphocytes and rare responding cells place very different demands on sampling. Each needs its own sampling depth before acquisition time becomes useful.\n\nThis comparison covers Sartorius iQue 5, Beckman Coulter CytoFLEX S with its specified plate loader, and Thermo Fisher Attune NxT with CytKick or CytKick Max. Attune CytPix is discussed where its imaging capability changes interpretation. These are representative screening and shared-lab configurations, not a complete cytometer catalog. The emphasis is on sample recovery, event statistics, panel performance, carryover and the work between loading a plate and accepting its results.\n\nHeadlinesFlow cytometers for drug discovery screening — HeadlinesThe finding | Technology and product evidence | Trade-offs and controls | What it means | \n\nChoose the biological population before the acquisition speed.MEASUREMENT OBJECTIVE | \nA well may contain live target cells, dead cells, debris, effector cells, aggregates and assay beads. Only some recorded events support a particular endpoint, and the relevant fraction can change with treatment. | \nA fixed total-event target gives inconsistent precision if a compound depletes the population of interest. A fixed acquisition time can give inconsistent counts when cell concentration varies. | \nDefine the necessary live-singlet or other target population before choosing stop rules. Inspect the count reaching the final gate in every well. Treat insufficient-event wells explicitly rather than letting a smooth concentration-response fit hide their uncertainty.Proposed assay-design and data-review rules. | \n\n\nFast sampling and deep sampling answer different needs.WORKFLOW FIT | \niQue 5 emphasizes microvolume plate sampling. CytoFLEX S offers a configurable analyzer with an optional 96-well loader. Attune configurations combine acoustic focusing with selectable sample flow and autosampler options. | \nMaximum event rate, plate cycle time and volume recovered are different quantities. A short advertised cycle may sample less liquid than the workflow beside it in the comparison. | \nChoose the configuration around required events per well, acceptable carryover and the panel's separation. Measure a representative plate from loading through analysis. Require the same biological acceptance criteria across candidates even when their acquisition methods differ.Sources: F1, F2, F4. Manufacturer positioning and proposed comparison basis. | \n\n\n\nSpecificationsFlow cytometers for drug discovery screening — SpecificationsThe finding | Technology and product evidence | Trade-offs and controls | What it means | \n\niQue 5 supports 96 and 384 well screening.IQUE CONFIGURATION | \nSartorius lists three- or four-laser iQue 5 configurations with 21 or 27 detection channels, a 1 µL minimum aspiration and minimum sampling times below five minutes for 96 wells and twenty minutes for 384 wells. | \nThat aspiration minimum leaves useful cell yield and required starting volume to be established for the method. Detection-channel totals should not be equated automatically with independently usable fluorescence markers. | \nConsider iQue for repeated microplate screening where integrated acquisition and plate analysis are valuable. Bring dilute and heterogeneous samples to the demonstration. Confirm the event yield, rejected wells and any additional sampling needed to meet the assay's count requirement.Sources: F1. Published minima, not a matched-sample benchmark. | \n\n\nThe named CytoFLEX loader is a 96 well configuration.CYTOFLEX CONFIGURATION | \nBeckman's CytoFLEX S page lists an optional 96-well sample loader. The C16574 loader supports standard and deep-well 96-well plates. Available optical configurations vary within the S family. | \nDo not infer 384-well acquisition from another CytoFLEX product, or confuse a sorter's plate-deposition capability with an analyzer's plate sampling. Sample reformatting would add a separate workflow step. | \nThis can be a practical shared-lab candidate when its exact panel and 96-well workflow meet demand. If 384-well acquisition is essential, require written confirmation of a compatible alternative configuration rather than treating the family name as evidence.Sources: F2, F3. Configuration-specific compatibility check. | \n\n\nAttune timing claims include a defined sampled volume.ATTUNE CONFIGURATION | \nThermo's NxT specification sheet lists CytKick Max Boost-mode times of 22 minutes for 96 wells and 88 minutes for 384 wells, with one mix, one rinse and analysis of 20 µL at 1,000 µL/min. | \nThese conditions differ from a minimum microvolume-sampling claim. They cannot establish a several-fold speed ranking against another instrument without matching event recovery and other acceptance criteria. | \nUse the published conditions as a reproducible starting point for a demonstration. Test the volume and rinse settings your cells require. Include setup, mixing, failed-well repeats and data review when calculating the practical number of plates per working day.Sources: F4. PDF p 5; conditions retained from the manufacturer table. | \n\n\nStarting well volume can be much larger than the analyzed volume.SAMPLE BUDGET | \nAutosampler methods need accessible liquid for probe positioning, mixing and collection. Minimum aspiration, analyzed volume and residual dead volume describe different stages of the operation. | \nFlat, U- and V-bottom wells have different liquid geometry. A plate that fits mechanically may still leave an unacceptable fraction of a scarce cell sample inaccessible under the chosen method. | \nMeasure cell recovery from the intended plate at the intended fill volume. Use counts before and after sampling where feasible. Ask how repeated sampling and mixing affect residual volume, and include that loss in the number of cells that must be prepared.Sources: F5. Proposed volume and recovery qualification. | \n\n\n\nFeaturesFlow cytometers for drug discovery screening — FeaturesThe finding | Technology and product evidence | Trade-offs and controls | What it means | \n\nHigh sample flow cannot abolish coincidence.ACOUSTIC FOCUSING | \nThermo describes acoustic focusing and sample flow up to 1,000 µL/min for Attune. Its capabilities guide qualifies a stated acquisition rate using a 10% coincidence condition based on Poisson statistics. | \nGood focusing does not guarantee that every arriving cell becomes a separately recorded event. Increasing concentration or delivery rate can change event losses and the reliability of apparent counts. | \nChallenge the same sample over a dilution series and sensible flow settings. Inspect event-rate linearity, abort information, pulse shape and population recovery. Select a setting that preserves the endpoint rather than automatically using the highest available flow rate.Sources: F6. Manufacturer principle and rate qualification; proposed test. | \n\n\nMore colors can make the decisive marker harder to resolve.PANEL DESIGN | \nNguyen and colleagues describe spillover spreading and a matrix for quantifying it. Correcting the mean contribution of fluorescence in another channel does not eliminate the propagated measurement spread. | \nBright coexpressed markers can broaden the distribution in a channel used for a dim biological response. Raw detector counts or a long fluorochrome list do not establish the panel's usable resolution. | \nCompare the actual panel on representative treated and untreated cells. Use appropriate single-stain and fluorescence-minus-one controls. Give important dim markers favorable fluorochrome and detector combinations, and inspect spreading when evaluating apparently similar configurations.Sources: F8. Primary-research principle; proposed panel comparison. | \n\n\nImaging can explain events that scatter gates leave ambiguous.ATTUNE CYTPIX OPTION | \nThermo's capabilities guide distinguishes Attune CytPix, which records brightfield images, from NxT, which does not provide that imaging feature. Images add information about the events passing through the instrument. | \nImage capture has its own throughput and data burden. It should not be assumed to provide an image for every fluorescence event under every acquisition setting, nor to replace a confocal cellular assay. | \nConsider CytPix when aggregates, cell morphology or unusual treated populations repeatedly complicate interpretation. Demonstrate how images are linked to gates and reviewed at screening scale. Keep any CytPix quotation and performance claims separate from the NxT configuration compared here.Sources: F6. Manufacturer distinction and application recommendation. | \n\n\n\nCapabilitiesFlow cytometers for drug discovery screening — CapabilitiesThe finding | Technology and product evidence | Trade-offs and controls | What it means | \n\nCells and secreted proteins can be measured in a shared sample.MULTIPLEX BIOLOGY | \nSartorius describes iQue assays combining cell phenotyping with bead-based secreted-protein detection in the same well. This can connect cellular state with an extracellular response within a common sample workflow. | \nThe bead population needs sufficient events and its own calibration. Secreted protein remains a well-level measurement; it cannot be assigned to an individual cell from shared-well detection alone. The reagents must also remain compatible. | \nEvaluate whether the combined assay reduces handling without compromising either endpoint. Track cell and bead counts independently. Confirm the dynamic range and dilution requirement for the secreted analyte rather than assuming the cell assay's preferred conditions serve both measurements.Sources: F7. Platform application; interpretation and proposed controls. | \n\n\nRare populations impose a count requirement.SAMPLING STATISTICS | \nFor a constructed population occurring at 0.1%, collecting 10,000 independent eligible cells gives an expected ten target events. At low frequency, the approximate relative counting uncertainty is 1/√k, where k is the expected target count. | \nTen expected target events imply about 32% relative counting uncertainty; 100 imply about 10%. Reaching 100 at 0.1% requires roughly 100,000 eligible cells. These are sampling estimates, not total assay CVs. | \nWork backward from the target precision to the eligible cell count and sample volume. Include losses from viability and singlet gates. Use statistical intervals for sparse observed counts, and avoid interpreting a handful of events as a finely measured potency shift.Constructed binomial/Poisson approximation; no instrument measurement. | \n\n\nThe acquisition rule can interact with compound biology.CYTOTOXIC AND CYTOSTATIC EFFECTS | \nA treatment may reduce cell number, alter scatter or change marker expression. A gate or stopping rule chosen on healthy controls can therefore affect treated wells differently. | \nExtending collection until every well supplies a fixed number of survivors can change the sampled volume and the elapsed time. Keeping a fixed duration can instead leave sparse wells with much poorer precision. | \nRetain sampled volume, collection time and gate counts alongside percentages. Decide whether the endpoint is frequency, intensity, absolute count or a combination. Validate the count method independently when cell number itself is part of the biological conclusion.Proposed interpretation and acquisition controls. | \n\n\n\nDownsidesFlow cytometers for drug discovery screening — DownsidesThe finding | Technology and product evidence | Trade-offs and controls | What it means | \n\nSmall carryover can matter greatly in a rare-cell assay.SAMPLE SEQUENCE | \nCarryover is residual material from an earlier sample entering a later one. Its consequence depends on the concentration and identity of the preceding sample, not simply on a reassuring average percentage. | \nIn a constructed case, a recipient sample has 10,000 cells including ten true target cells. Adding ten target cells from the previous sample raises the observed target fraction from 0.10% to about 0.20%. | \nTest high–blank–low sequences with a distinguishable cell or bead population and the intended rinse program. Inspect blanks immediately after the strongest samples. Adequate cleaning and sampling design prevent a problem that arithmetic subtraction cannot fully repair: the contaminating events have already entered the data.Constructed contamination example and proposed test. | \n\n\nCells continue changing while a plate waits.SETTLING AND TEMPERATURE | \nThe CytKick manual describes configurable sample mixing and wash operations. Those operations contribute to cycle time and determine the physical treatment of each well before acquisition. | \nSettling, clumping and biological drift can make early and late wells differ. Stable temperature helps control one variable, but the suitable temperature depends on the live-cell or fixed-cell assay rather than a universal room-temperature rule. | \nCompare early and late control wells and retain acquisition order. Qualify mixing for both uniform sampling and cell health. Use validated holding conditions and limits on queue time; record whether a cooling accessory controls sample temperature or merely slows warming.Sources: F5. Manual-supported operations and proposed queue qualification. | \n\n\nPlate throughput can move the bottleneck into analysis.DATA WORKLOAD | \nA screen produces many population distributions, gate decisions and quality exceptions. The analysis must preserve plate identity, controls, treatment metadata and the relationship between raw events and reported results. | \nAutomated gates can fail systematically on a treatment-shifted population. Manual review of every plot can become the dominant labor cost, while silent exclusion of difficult wells can bias the hit list. | \nDemonstrate a plate with deliberately difficult samples. Measure the time to an auditable result, including failed-well review. Require access to raw event files, analysis settings and the reason each well was accepted or rejected.Proposed software acceptance test. | \n\n\n\nAdvantagesFlow cytometers for drug discovery screening — AdvantagesThe finding | Technology and product evidence | Trade-offs and controls | What it means | \n\niQue deserves a place on a screening-focused shortlist.REPEATED PLATE WORK | \nThe iQue platform combines plate acquisition with Forecyt analysis and screening-oriented assay workflows. Its microvolume approach is a practical candidate when samples contain enough eligible events at the available concentration. | \nThe screening advantage must survive the assay's required sampling depth and controls. A very dilute sample or rare endpoint may need more acquisition than a minimum-time specification represents. | \nTest the full screen recipe, from layout import through concentration-response analysis. Include cell loss, interference and missing-well cases. Favor the integrated workflow when it reduces hands-on review while preserving traceability and the required biological precision.Sources: F1. Configuration-based recommendation, not an independent speed ranking. | \n\n\nCytoFLEX S can suit a shared 96 well laboratory.FLEXIBLE ANALYZER USE | \nCytoFLEX S offers multiple laser/filter configurations and CytExpert acquisition and analysis. Beckman describes an API for external control and integration with its liquid-handling platforms. | \nFlexibility can be valuable when users bring different panels, but method changeover, training and maintenance still consume time. Optional automation and optical upgrades must be included in the proposed configuration. | \nAssess it with the core lab's recurring panels and a realistic schedule of tube and plate work. Make 96-well throughput a measured acceptance criterion. Select it for a demonstrated workload fit rather than assuming a configurable analyzer automatically behaves like a dedicated screening workcell.Sources: F2. Manufacturer features and workflow recommendation. | \n\n\nAttune merits testing when useful sampling volume is a priority.VOLUME AND EVENT YIELD | \nAttune's acoustic-focusing approach provides selectable high sample flow, and its autosampler methods specify analyzed volume and mixing. This gives a concrete basis for a demonstration with relatively dilute samples. | \nMore sampled liquid is useful only while coincidence, background, carryover and population recovery remain acceptable. Additional sample volume also increases the number of cells and reagents the assay must supply. | \nCompare accepted events per microliter and per minute over the relevant concentration range. For scarce samples, include accessible volume and residual loss. Use the resulting data to choose an acquisition method before comparing end-to-end plate productivity.Sources: F4, F6. Mechanistic and workflow inference; proposed measurement. | \n\n\n\nNotable DetailsFlow cytometers for drug discovery screening — Notable DetailsThe finding | Technology and product evidence | Trade-offs and controls | What it means | \n\nUse one challenge plate to compare the complete methods.DEMONSTRATION PLAN | \nInclude abundant and rare target populations, a dilution series, a bright interfering marker, aggregates and high–blank–low sequences. Distribute stable controls so acquisition-order effects can be detected. | \nKeep biological preparation comparable while allowing each supplier to optimize a documented method. Artificially forcing identical flow settings can disadvantage a different sampling architecture without creating a fair scientific comparison. | \nCompare final-gate counts, dim-population separation, carryover, rejected events, missed wells and review time. Set acceptable errors before the demonstration. Repeat on another day to test whether the method can be handed to the operators who will actually use it.Proposed matched-objective benchmark. | \n\n\nCost the usable results and the labor behind them.PURCHASING DECISION | \nThe relevant quote includes the cytometer configuration, loader, software seats, integration, QC materials, cleaning supplies, service and training. A screening workflow may also need sample preparation automation and protected plate storage. | \nNeither acquisition specifications nor list-price fragments establish total cost per accepted well. Instrument downtime and the time spent resolving bad gates can exceed the apparent saving from a faster plate cycle. | \nBuild the comparison around a stated annual workload and a defined endpoint. Ask suppliers to provide the configuration used in the demonstration and the support needed to maintain it. Record which future assays the proposed configuration can support, and which would require another purchase.Procurement framework; no price or service-performance ranking claimed. | \n\n\n\nAbout the sources\n\nManufacturer specifications describe the named product and configuration; they are not independent all-vendor benchmarks. Row-level source IDs link to the references below. Calculations and practical interpretations are identified separately. No physical comparison or procurement quotation is represented by these tables.\n\nF1 iQue 5 specifications\n\nF2 CytoFLEX S specifications\n\nF3 CytoFLEX plate loader C16574\n\nF4 Attune NxT specification sheet\n\nF5 CytKick and CytKick MAX user guide\n\nF6 Thermo flow cytometry capabilities guide\n\nF7 iQue cells and secreted proteins\n\nF8 Nguyen et al 2013 — Quantifying spillover spreading for comparing instrument performance and aiding in multicolor panel design", "sections": [ { "id": "introduction", "heading": "Introduction", "blocks": [ { "type": "p", "text": "A plate can finish quickly and still leave the experiment short of cells. For screening flow cytometry, count throughput in wells that yield enough valid events from the population being studied. Bright beads, abundant lymphocytes and rare responding cells place very different demands on sampling. Each needs its own sampling depth before acquisition time becomes useful.", "html": "A plate can finish quickly and still leave the experiment short of cells. For screening flow cytometry, count throughput in wells that yield enough valid events from the population being studied. Bright beads, abundant lymphocytes and rare responding cells place very different demands on sampling. Each needs its own sampling depth before acquisition time becomes useful.
" }, { "type": "p", "text": "This comparison covers Sartorius iQue 5, Beckman Coulter CytoFLEX S with its specified plate loader, and Thermo Fisher Attune NxT with CytKick or CytKick Max. Attune CytPix is discussed where its imaging capability changes interpretation. These are representative screening and shared-lab configurations, not a complete cytometer catalog. The emphasis is on sample recovery, event statistics, panel performance, carryover and the work between loading a plate and accepting its results.", "html": "This comparison covers Sartorius iQue 5, Beckman Coulter CytoFLEX S with its specified plate loader, and Thermo Fisher Attune NxT with CytKick or CytKick Max. Attune CytPix is discussed where its imaging capability changes interpretation. These are representative screening and shared-lab configurations, not a complete cytometer catalog. The emphasis is on sample recovery, event statistics, panel performance, carryover and the work between loading a plate and accepting its results.
" }, { "type": "section", "text": "HeadlinesFlow cytometers for drug discovery screening — HeadlinesThe finding | Technology and product evidence | Trade-offs and controls | What it means | \n\nChoose the biological population before the acquisition speed.MEASUREMENT OBJECTIVE | \nA well may contain live target cells, dead cells, debris, effector cells, aggregates and assay beads. Only some recorded events support a particular endpoint, and the relevant fraction can change with treatment. | \nA fixed total-event target gives inconsistent precision if a compound depletes the population of interest. A fixed acquisition time can give inconsistent counts when cell concentration varies. | \nDefine the necessary live-singlet or other target population before choosing stop rules. Inspect the count reaching the final gate in every well. Treat insufficient-event wells explicitly rather than letting a smooth concentration-response fit hide their uncertainty.Proposed assay-design and data-review rules. | \n\n\nFast sampling and deep sampling answer different needs.WORKFLOW FIT | \niQue 5 emphasizes microvolume plate sampling. CytoFLEX S offers a configurable analyzer with an optional 96-well loader. Attune configurations combine acoustic focusing with selectable sample flow and autosampler options. | \nMaximum event rate, plate cycle time and volume recovered are different quantities. A short advertised cycle may sample less liquid than the workflow beside it in the comparison. | \nChoose the configuration around required events per well, acceptable carryover and the panel's separation. Measure a representative plate from loading through analysis. Require the same biological acceptance criteria across candidates even when their acquisition methods differ.Sources: F1, F2, F4. Manufacturer positioning and proposed comparison basis. | \n\n", "html": "| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Choose the biological population before the acquisition speed. MEASUREMENT OBJECTIVE | \nA well may contain live target cells, dead cells, debris, effector cells, aggregates and assay beads. Only some recorded events support a particular endpoint, and the relevant fraction can change with treatment. | \nA fixed total-event target gives inconsistent precision if a compound depletes the population of interest. A fixed acquisition time can give inconsistent counts when cell concentration varies. | \nDefine the necessary live-singlet or other target population before choosing stop rules. Inspect the count reaching the final gate in every well. Treat insufficient-event wells explicitly rather than letting a smooth concentration-response fit hide their uncertainty. Proposed assay-design and data-review rules. | \n
Fast sampling and deep sampling answer different needs. WORKFLOW FIT | \niQue 5 emphasizes microvolume plate sampling. CytoFLEX S offers a configurable analyzer with an optional 96-well loader. Attune configurations combine acoustic focusing with selectable sample flow and autosampler options. | \nMaximum event rate, plate cycle time and volume recovered are different quantities. A short advertised cycle may sample less liquid than the workflow beside it in the comparison. | \nChoose the configuration around required events per well, acceptable carryover and the panel's separation. Measure a representative plate from loading through analysis. Require the same biological acceptance criteria across candidates even when their acquisition methods differ. Sources: F1, F2, F4. Manufacturer positioning and proposed comparison basis. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
iQue 5 supports 96 and 384 well screening. IQUE CONFIGURATION | \nSartorius lists three- or four-laser iQue 5 configurations with 21 or 27 detection channels, a 1 µL minimum aspiration and minimum sampling times below five minutes for 96 wells and twenty minutes for 384 wells. | \nThat aspiration minimum leaves useful cell yield and required starting volume to be established for the method. Detection-channel totals should not be equated automatically with independently usable fluorescence markers. | \nConsider iQue for repeated microplate screening where integrated acquisition and plate analysis are valuable. Bring dilute and heterogeneous samples to the demonstration. Confirm the event yield, rejected wells and any additional sampling needed to meet the assay's count requirement. Sources: F1. Published minima, not a matched-sample benchmark. | \n
The named CytoFLEX loader is a 96 well configuration. CYTOFLEX CONFIGURATION | \nBeckman's CytoFLEX S page lists an optional 96-well sample loader. The C16574 loader supports standard and deep-well 96-well plates. Available optical configurations vary within the S family. | \nDo not infer 384-well acquisition from another CytoFLEX product, or confuse a sorter's plate-deposition capability with an analyzer's plate sampling. Sample reformatting would add a separate workflow step. | \nThis can be a practical shared-lab candidate when its exact panel and 96-well workflow meet demand. If 384-well acquisition is essential, require written confirmation of a compatible alternative configuration rather than treating the family name as evidence. Sources: F2, F3. Configuration-specific compatibility check. | \n
Attune timing claims include a defined sampled volume. ATTUNE CONFIGURATION | \nThermo's NxT specification sheet lists CytKick Max Boost-mode times of 22 minutes for 96 wells and 88 minutes for 384 wells, with one mix, one rinse and analysis of 20 µL at 1,000 µL/min. | \nThese conditions differ from a minimum microvolume-sampling claim. They cannot establish a several-fold speed ranking against another instrument without matching event recovery and other acceptance criteria. | \nUse the published conditions as a reproducible starting point for a demonstration. Test the volume and rinse settings your cells require. Include setup, mixing, failed-well repeats and data review when calculating the practical number of plates per working day. Sources: F4. PDF p 5; conditions retained from the manufacturer table. | \n
Starting well volume can be much larger than the analyzed volume. SAMPLE BUDGET | \nAutosampler methods need accessible liquid for probe positioning, mixing and collection. Minimum aspiration, analyzed volume and residual dead volume describe different stages of the operation. | \nFlat, U- and V-bottom wells have different liquid geometry. A plate that fits mechanically may still leave an unacceptable fraction of a scarce cell sample inaccessible under the chosen method. | \nMeasure cell recovery from the intended plate at the intended fill volume. Use counts before and after sampling where feasible. Ask how repeated sampling and mixing affect residual volume, and include that loss in the number of cells that must be prepared. Sources: F5. Proposed volume and recovery qualification. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
High sample flow cannot abolish coincidence. ACOUSTIC FOCUSING | \nThermo describes acoustic focusing and sample flow up to 1,000 µL/min for Attune. Its capabilities guide qualifies a stated acquisition rate using a 10% coincidence condition based on Poisson statistics. | \nGood focusing does not guarantee that every arriving cell becomes a separately recorded event. Increasing concentration or delivery rate can change event losses and the reliability of apparent counts. | \nChallenge the same sample over a dilution series and sensible flow settings. Inspect event-rate linearity, abort information, pulse shape and population recovery. Select a setting that preserves the endpoint rather than automatically using the highest available flow rate. Sources: F6. Manufacturer principle and rate qualification; proposed test. | \n
More colors can make the decisive marker harder to resolve. PANEL DESIGN | \nNguyen and colleagues describe spillover spreading and a matrix for quantifying it. Correcting the mean contribution of fluorescence in another channel does not eliminate the propagated measurement spread. | \nBright coexpressed markers can broaden the distribution in a channel used for a dim biological response. Raw detector counts or a long fluorochrome list do not establish the panel's usable resolution. | \nCompare the actual panel on representative treated and untreated cells. Use appropriate single-stain and fluorescence-minus-one controls. Give important dim markers favorable fluorochrome and detector combinations, and inspect spreading when evaluating apparently similar configurations. Sources: F8. Primary-research principle; proposed panel comparison. | \n
Imaging can explain events that scatter gates leave ambiguous. ATTUNE CYTPIX OPTION | \nThermo's capabilities guide distinguishes Attune CytPix, which records brightfield images, from NxT, which does not provide that imaging feature. Images add information about the events passing through the instrument. | \nImage capture has its own throughput and data burden. It should not be assumed to provide an image for every fluorescence event under every acquisition setting, nor to replace a confocal cellular assay. | \nConsider CytPix when aggregates, cell morphology or unusual treated populations repeatedly complicate interpretation. Demonstrate how images are linked to gates and reviewed at screening scale. Keep any CytPix quotation and performance claims separate from the NxT configuration compared here. Sources: F6. Manufacturer distinction and application recommendation. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Cells and secreted proteins can be measured in a shared sample. MULTIPLEX BIOLOGY | \nSartorius describes iQue assays combining cell phenotyping with bead-based secreted-protein detection in the same well. This can connect cellular state with an extracellular response within a common sample workflow. | \nThe bead population needs sufficient events and its own calibration. Secreted protein remains a well-level measurement; it cannot be assigned to an individual cell from shared-well detection alone. The reagents must also remain compatible. | \nEvaluate whether the combined assay reduces handling without compromising either endpoint. Track cell and bead counts independently. Confirm the dynamic range and dilution requirement for the secreted analyte rather than assuming the cell assay's preferred conditions serve both measurements. Sources: F7. Platform application; interpretation and proposed controls. | \n
Rare populations impose a count requirement. SAMPLING STATISTICS | \nFor a constructed population occurring at 0.1%, collecting 10,000 independent eligible cells gives an expected ten target events. At low frequency, the approximate relative counting uncertainty is 1/√k, where k is the expected target count. | \nTen expected target events imply about 32% relative counting uncertainty; 100 imply about 10%. Reaching 100 at 0.1% requires roughly 100,000 eligible cells. These are sampling estimates, not total assay CVs. | \nWork backward from the target precision to the eligible cell count and sample volume. Include losses from viability and singlet gates. Use statistical intervals for sparse observed counts, and avoid interpreting a handful of events as a finely measured potency shift. Constructed binomial/Poisson approximation; no instrument measurement. | \n
The acquisition rule can interact with compound biology. CYTOTOXIC AND CYTOSTATIC EFFECTS | \nA treatment may reduce cell number, alter scatter or change marker expression. A gate or stopping rule chosen on healthy controls can therefore affect treated wells differently. | \nExtending collection until every well supplies a fixed number of survivors can change the sampled volume and the elapsed time. Keeping a fixed duration can instead leave sparse wells with much poorer precision. | \nRetain sampled volume, collection time and gate counts alongside percentages. Decide whether the endpoint is frequency, intensity, absolute count or a combination. Validate the count method independently when cell number itself is part of the biological conclusion. Proposed interpretation and acquisition controls. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Small carryover can matter greatly in a rare-cell assay. SAMPLE SEQUENCE | \nCarryover is residual material from an earlier sample entering a later one. Its consequence depends on the concentration and identity of the preceding sample, not simply on a reassuring average percentage. | \nIn a constructed case, a recipient sample has 10,000 cells including ten true target cells. Adding ten target cells from the previous sample raises the observed target fraction from 0.10% to about 0.20%. | \nTest high–blank–low sequences with a distinguishable cell or bead population and the intended rinse program. Inspect blanks immediately after the strongest samples. Adequate cleaning and sampling design prevent a problem that arithmetic subtraction cannot fully repair: the contaminating events have already entered the data. Constructed contamination example and proposed test. | \n
Cells continue changing while a plate waits. SETTLING AND TEMPERATURE | \nThe CytKick manual describes configurable sample mixing and wash operations. Those operations contribute to cycle time and determine the physical treatment of each well before acquisition. | \nSettling, clumping and biological drift can make early and late wells differ. Stable temperature helps control one variable, but the suitable temperature depends on the live-cell or fixed-cell assay rather than a universal room-temperature rule. | \nCompare early and late control wells and retain acquisition order. Qualify mixing for both uniform sampling and cell health. Use validated holding conditions and limits on queue time; record whether a cooling accessory controls sample temperature or merely slows warming. Sources: F5. Manual-supported operations and proposed queue qualification. | \n
Plate throughput can move the bottleneck into analysis. DATA WORKLOAD | \nA screen produces many population distributions, gate decisions and quality exceptions. The analysis must preserve plate identity, controls, treatment metadata and the relationship between raw events and reported results. | \nAutomated gates can fail systematically on a treatment-shifted population. Manual review of every plot can become the dominant labor cost, while silent exclusion of difficult wells can bias the hit list. | \nDemonstrate a plate with deliberately difficult samples. Measure the time to an auditable result, including failed-well review. Require access to raw event files, analysis settings and the reason each well was accepted or rejected. Proposed software acceptance test. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
iQue deserves a place on a screening-focused shortlist. REPEATED PLATE WORK | \nThe iQue platform combines plate acquisition with Forecyt analysis and screening-oriented assay workflows. Its microvolume approach is a practical candidate when samples contain enough eligible events at the available concentration. | \nThe screening advantage must survive the assay's required sampling depth and controls. A very dilute sample or rare endpoint may need more acquisition than a minimum-time specification represents. | \nTest the full screen recipe, from layout import through concentration-response analysis. Include cell loss, interference and missing-well cases. Favor the integrated workflow when it reduces hands-on review while preserving traceability and the required biological precision. Sources: F1. Configuration-based recommendation, not an independent speed ranking. | \n
CytoFLEX S can suit a shared 96 well laboratory. FLEXIBLE ANALYZER USE | \nCytoFLEX S offers multiple laser/filter configurations and CytExpert acquisition and analysis. Beckman describes an API for external control and integration with its liquid-handling platforms. | \nFlexibility can be valuable when users bring different panels, but method changeover, training and maintenance still consume time. Optional automation and optical upgrades must be included in the proposed configuration. | \nAssess it with the core lab's recurring panels and a realistic schedule of tube and plate work. Make 96-well throughput a measured acceptance criterion. Select it for a demonstrated workload fit rather than assuming a configurable analyzer automatically behaves like a dedicated screening workcell. Sources: F2. Manufacturer features and workflow recommendation. | \n
Attune merits testing when useful sampling volume is a priority. VOLUME AND EVENT YIELD | \nAttune's acoustic-focusing approach provides selectable high sample flow, and its autosampler methods specify analyzed volume and mixing. This gives a concrete basis for a demonstration with relatively dilute samples. | \nMore sampled liquid is useful only while coincidence, background, carryover and population recovery remain acceptable. Additional sample volume also increases the number of cells and reagents the assay must supply. | \nCompare accepted events per microliter and per minute over the relevant concentration range. For scarce samples, include accessible volume and residual loss. Use the resulting data to choose an acquisition method before comparing end-to-end plate productivity. Sources: F4, F6. Mechanistic and workflow inference; proposed measurement. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Use one challenge plate to compare the complete methods. DEMONSTRATION PLAN | \nInclude abundant and rare target populations, a dilution series, a bright interfering marker, aggregates and high–blank–low sequences. Distribute stable controls so acquisition-order effects can be detected. | \nKeep biological preparation comparable while allowing each supplier to optimize a documented method. Artificially forcing identical flow settings can disadvantage a different sampling architecture without creating a fair scientific comparison. | \nCompare final-gate counts, dim-population separation, carryover, rejected events, missed wells and review time. Set acceptable errors before the demonstration. Repeat on another day to test whether the method can be handed to the operators who will actually use it. Proposed matched-objective benchmark. | \n
Cost the usable results and the labor behind them. PURCHASING DECISION | \nThe relevant quote includes the cytometer configuration, loader, software seats, integration, QC materials, cleaning supplies, service and training. A screening workflow may also need sample preparation automation and protected plate storage. | \nNeither acquisition specifications nor list-price fragments establish total cost per accepted well. Instrument downtime and the time spent resolving bad gates can exceed the apparent saving from a faster plate cycle. | \nBuild the comparison around a stated annual workload and a defined endpoint. Ask suppliers to provide the configuration used in the demonstration and the support needed to maintain it. Record which future assays the proposed configuration can support, and which would require another purchase. Procurement framework; no price or service-performance ranking claimed. | \n
Manufacturer specifications describe the named product and configuration; they are not independent all-vendor benchmarks. Row-level source IDs link to the references below. Calculations and practical interpretations are identified separately. No physical comparison or procurement quotation is represented by these tables.
" }, { "type": "p", "text": "F1 iQue 5 specifications", "html": "" }, { "type": "p", "text": "F2 CytoFLEX S specifications", "html": "" }, { "type": "p", "text": "F3 CytoFLEX plate loader C16574", "html": "F3 CytoFLEX plate loader C16574
" }, { "type": "p", "text": "F4 Attune NxT specification sheet", "html": "F4 Attune NxT specification sheet
" }, { "type": "p", "text": "F5 CytKick and CytKick MAX user guide", "html": "F5 CytKick and CytKick MAX user guide
" }, { "type": "p", "text": "F6 Thermo flow cytometry capabilities guide", "html": "F6 Thermo flow cytometry capabilities guide
" }, { "type": "p", "text": "F7 iQue cells and secreted proteins", "html": "" }, { "type": "p", "text": "F8 Nguyen et al 2013 — Quantifying spillover spreading for comparing instrument performance and aiding in multicolor panel design", "html": "" } ] } ], "references": [ { "id": "ref-f1", "citation": "F1 iQue 5 specifications", "urls": [ "https://www.sartorius.com/en/products/high-throughput-cytometry/high-throughput-cytometry-instruments/ique5" ] }, { "id": "ref-f2", "citation": "F2 CytoFLEX S specifications", "urls": [ "https://www.beckman.com/flow-cytometry/research-flow-cytometers/cytoflex-s" ] }, { "id": "ref-f3", "citation": "F3 CytoFLEX plate loader C16574", "urls": [ "https://www.beckman.com/supplies/plate-loaders/C16574" ] }, { "id": "ref-f4", "citation": "F4 Attune NxT specification sheet", "urls": [ "https://documents.thermofisher.com/TFS-Assets/LSG/brochures/attune-nxt-flow-cytometer-spec-sheet.pdf" ] }, { "id": "ref-f5", "citation": "F5 CytKick and CytKick MAX user guide", "urls": [ "https://documents.thermofisher.com/TFS-Assets/LSG/manuals/MAN0018351_CytKick_CytKickMAX_Autosampler_UG.pdf" ] }, { "id": "ref-f6", "citation": "F6 Thermo flow cytometry capabilities guide", "urls": [ "https://assets.thermofisher.com/TFS-Assets/BID/brochures/flow-cytometry-capabilities-guide-brochure.pdf" ] }, { "id": "ref-f7", "citation": "F7 iQue cells and secreted proteins", "urls": [ "https://www.sartorius.com/en/products/high-throughput-cytometry/ique-cytometry-cell-phenotyping-and-secreted-protein-detection-within-the-same-well" ] }, { "id": "ref-f8", "citation": "F8 Nguyen et al 2013 — Quantifying spillover spreading for comparing instrument performance and aiding in multicolor panel design", "urls": [ "https://doi.org/10.1002/cyto.a.22251" ] } ], "equations": [], "tables": [ { "caption": "Flow cytometers for drug discovery screening — Headlines", "rows": [ [ "The finding", "Technology and product evidence", "Trade-offs and controls", "What it means" ], [ "Choose the biological population before the acquisition speed.MEASUREMENT OBJECTIVE", "A well may contain live target cells, dead cells, debris, effector cells, aggregates and assay beads. Only some recorded events support a particular endpoint, and the relevant fraction can change with treatment.", "A fixed total-event target gives inconsistent precision if a compound depletes the population of interest. A fixed acquisition time can give inconsistent counts when cell concentration varies.", "Define the necessary live-singlet or other target population before choosing stop rules. Inspect the count reaching the final gate in every well. Treat insufficient-event wells explicitly rather than letting a smooth concentration-response fit hide their uncertainty.Proposed assay-design and data-review rules." ], [ "Fast sampling and deep sampling answer different needs.WORKFLOW FIT", "iQue 5 emphasizes microvolume plate sampling. CytoFLEX S offers a configurable analyzer with an optional 96-well loader. Attune configurations combine acoustic focusing with selectable sample flow and autosampler options.", "Maximum event rate, plate cycle time and volume recovered are different quantities. A short advertised cycle may sample less liquid than the workflow beside it in the comparison.", "Choose the configuration around required events per well, acceptable carryover and the panel's separation. Measure a representative plate from loading through analysis. Require the same biological acceptance criteria across candidates even when their acquisition methods differ.Sources: F1, F2, F4. Manufacturer positioning and proposed comparison basis." ] ], "data_kind": "source comparison and stated illustrative calculations" }, { "caption": "Flow cytometers for drug discovery screening — Specifications", "rows": [ [ "The finding", "Technology and product evidence", "Trade-offs and controls", "What it means" ], [ "iQue 5 supports 96 and 384 well screening.IQUE CONFIGURATION", "Sartorius lists three- or four-laser iQue 5 configurations with 21 or 27 detection channels, a 1 µL minimum aspiration and minimum sampling times below five minutes for 96 wells and twenty minutes for 384 wells.", "That aspiration minimum leaves useful cell yield and required starting volume to be established for the method. Detection-channel totals should not be equated automatically with independently usable fluorescence markers.", "Consider iQue for repeated microplate screening where integrated acquisition and plate analysis are valuable. Bring dilute and heterogeneous samples to the demonstration. Confirm the event yield, rejected wells and any additional sampling needed to meet the assay's count requirement.Sources: F1. Published minima, not a matched-sample benchmark." ], [ "The named CytoFLEX loader is a 96 well configuration.CYTOFLEX CONFIGURATION", "Beckman's CytoFLEX S page lists an optional 96-well sample loader. The C16574 loader supports standard and deep-well 96-well plates. Available optical configurations vary within the S family.", "Do not infer 384-well acquisition from another CytoFLEX product, or confuse a sorter's plate-deposition capability with an analyzer's plate sampling. Sample reformatting would add a separate workflow step.", "This can be a practical shared-lab candidate when its exact panel and 96-well workflow meet demand. If 384-well acquisition is essential, require written confirmation of a compatible alternative configuration rather than treating the family name as evidence.Sources: F2, F3. Configuration-specific compatibility check." ], [ "Attune timing claims include a defined sampled volume.ATTUNE CONFIGURATION", "Thermo's NxT specification sheet lists CytKick Max Boost-mode times of 22 minutes for 96 wells and 88 minutes for 384 wells, with one mix, one rinse and analysis of 20 µL at 1,000 µL/min.", "These conditions differ from a minimum microvolume-sampling claim. They cannot establish a several-fold speed ranking against another instrument without matching event recovery and other acceptance criteria.", "Use the published conditions as a reproducible starting point for a demonstration. Test the volume and rinse settings your cells require. Include setup, mixing, failed-well repeats and data review when calculating the practical number of plates per working day.Sources: F4. PDF p 5; conditions retained from the manufacturer table." ], [ "Starting well volume can be much larger than the analyzed volume.SAMPLE BUDGET", "Autosampler methods need accessible liquid for probe positioning, mixing and collection. Minimum aspiration, analyzed volume and residual dead volume describe different stages of the operation.", "Flat, U- and V-bottom wells have different liquid geometry. A plate that fits mechanically may still leave an unacceptable fraction of a scarce cell sample inaccessible under the chosen method.", "Measure cell recovery from the intended plate at the intended fill volume. Use counts before and after sampling where feasible. Ask how repeated sampling and mixing affect residual volume, and include that loss in the number of cells that must be prepared.Sources: F5. Proposed volume and recovery qualification." ] ], "data_kind": "source comparison and stated illustrative calculations" }, { "caption": "Flow cytometers for drug discovery screening — Features", "rows": [ [ "The finding", "Technology and product evidence", "Trade-offs and controls", "What it means" ], [ "High sample flow cannot abolish coincidence.ACOUSTIC FOCUSING", "Thermo describes acoustic focusing and sample flow up to 1,000 µL/min for Attune. Its capabilities guide qualifies a stated acquisition rate using a 10% coincidence condition based on Poisson statistics.", "Good focusing does not guarantee that every arriving cell becomes a separately recorded event. Increasing concentration or delivery rate can change event losses and the reliability of apparent counts.", "Challenge the same sample over a dilution series and sensible flow settings. Inspect event-rate linearity, abort information, pulse shape and population recovery. Select a setting that preserves the endpoint rather than automatically using the highest available flow rate.Sources: F6. Manufacturer principle and rate qualification; proposed test." ], [ "More colors can make the decisive marker harder to resolve.PANEL DESIGN", "Nguyen and colleagues describe spillover spreading and a matrix for quantifying it. Correcting the mean contribution of fluorescence in another channel does not eliminate the propagated measurement spread.", "Bright coexpressed markers can broaden the distribution in a channel used for a dim biological response. Raw detector counts or a long fluorochrome list do not establish the panel's usable resolution.", "Compare the actual panel on representative treated and untreated cells. Use appropriate single-stain and fluorescence-minus-one controls. Give important dim markers favorable fluorochrome and detector combinations, and inspect spreading when evaluating apparently similar configurations.Sources: F8. Primary-research principle; proposed panel comparison." ], [ "Imaging can explain events that scatter gates leave ambiguous.ATTUNE CYTPIX OPTION", "Thermo's capabilities guide distinguishes Attune CytPix, which records brightfield images, from NxT, which does not provide that imaging feature. Images add information about the events passing through the instrument.", "Image capture has its own throughput and data burden. It should not be assumed to provide an image for every fluorescence event under every acquisition setting, nor to replace a confocal cellular assay.", "Consider CytPix when aggregates, cell morphology or unusual treated populations repeatedly complicate interpretation. Demonstrate how images are linked to gates and reviewed at screening scale. Keep any CytPix quotation and performance claims separate from the NxT configuration compared here.Sources: F6. Manufacturer distinction and application recommendation." ] ], "data_kind": "source comparison and stated illustrative calculations" }, { "caption": "Flow cytometers for drug discovery screening — Capabilities", "rows": [ [ "The finding", "Technology and product evidence", "Trade-offs and controls", "What it means" ], [ "Cells and secreted proteins can be measured in a shared sample.MULTIPLEX BIOLOGY", "Sartorius describes iQue assays combining cell phenotyping with bead-based secreted-protein detection in the same well. This can connect cellular state with an extracellular response within a common sample workflow.", "The bead population needs sufficient events and its own calibration. Secreted protein remains a well-level measurement; it cannot be assigned to an individual cell from shared-well detection alone. The reagents must also remain compatible.", "Evaluate whether the combined assay reduces handling without compromising either endpoint. Track cell and bead counts independently. Confirm the dynamic range and dilution requirement for the secreted analyte rather than assuming the cell assay's preferred conditions serve both measurements.Sources: F7. Platform application; interpretation and proposed controls." ], [ "Rare populations impose a count requirement.SAMPLING STATISTICS", "For a constructed population occurring at 0.1%, collecting 10,000 independent eligible cells gives an expected ten target events. At low frequency, the approximate relative counting uncertainty is 1/√k, where k is the expected target count.", "Ten expected target events imply about 32% relative counting uncertainty; 100 imply about 10%. Reaching 100 at 0.1% requires roughly 100,000 eligible cells. These are sampling estimates, not total assay CVs.", "Work backward from the target precision to the eligible cell count and sample volume. Include losses from viability and singlet gates. Use statistical intervals for sparse observed counts, and avoid interpreting a handful of events as a finely measured potency shift.Constructed binomial/Poisson approximation; no instrument measurement." ], [ "The acquisition rule can interact with compound biology.CYTOTOXIC AND CYTOSTATIC EFFECTS", "A treatment may reduce cell number, alter scatter or change marker expression. A gate or stopping rule chosen on healthy controls can therefore affect treated wells differently.", "Extending collection until every well supplies a fixed number of survivors can change the sampled volume and the elapsed time. Keeping a fixed duration can instead leave sparse wells with much poorer precision.", "Retain sampled volume, collection time and gate counts alongside percentages. Decide whether the endpoint is frequency, intensity, absolute count or a combination. Validate the count method independently when cell number itself is part of the biological conclusion.Proposed interpretation and acquisition controls." ] ], "data_kind": "source comparison and stated illustrative calculations" }, { "caption": "Flow cytometers for drug discovery screening — Downsides", "rows": [ [ "The finding", "Technology and product evidence", "Trade-offs and controls", "What it means" ], [ "Small carryover can matter greatly in a rare-cell assay.SAMPLE SEQUENCE", "Carryover is residual material from an earlier sample entering a later one. Its consequence depends on the concentration and identity of the preceding sample, not simply on a reassuring average percentage.", "In a constructed case, a recipient sample has 10,000 cells including ten true target cells. Adding ten target cells from the previous sample raises the observed target fraction from 0.10% to about 0.20%.", "Test high–blank–low sequences with a distinguishable cell or bead population and the intended rinse program. Inspect blanks immediately after the strongest samples. Adequate cleaning and sampling design prevent a problem that arithmetic subtraction cannot fully repair: the contaminating events have already entered the data.Constructed contamination example and proposed test." ], [ "Cells continue changing while a plate waits.SETTLING AND TEMPERATURE", "The CytKick manual describes configurable sample mixing and wash operations. Those operations contribute to cycle time and determine the physical treatment of each well before acquisition.", "Settling, clumping and biological drift can make early and late wells differ. Stable temperature helps control one variable, but the suitable temperature depends on the live-cell or fixed-cell assay rather than a universal room-temperature rule.", "Compare early and late control wells and retain acquisition order. Qualify mixing for both uniform sampling and cell health. Use validated holding conditions and limits on queue time; record whether a cooling accessory controls sample temperature or merely slows warming.Sources: F5. Manual-supported operations and proposed queue qualification." ], [ "Plate throughput can move the bottleneck into analysis.DATA WORKLOAD", "A screen produces many population distributions, gate decisions and quality exceptions. The analysis must preserve plate identity, controls, treatment metadata and the relationship between raw events and reported results.", "Automated gates can fail systematically on a treatment-shifted population. Manual review of every plot can become the dominant labor cost, while silent exclusion of difficult wells can bias the hit list.", "Demonstrate a plate with deliberately difficult samples. Measure the time to an auditable result, including failed-well review. Require access to raw event files, analysis settings and the reason each well was accepted or rejected.Proposed software acceptance test." ] ], "data_kind": "source comparison and stated illustrative calculations" }, { "caption": "Flow cytometers for drug discovery screening — Advantages", "rows": [ [ "The finding", "Technology and product evidence", "Trade-offs and controls", "What it means" ], [ "iQue deserves a place on a screening-focused shortlist.REPEATED PLATE WORK", "The iQue platform combines plate acquisition with Forecyt analysis and screening-oriented assay workflows. Its microvolume approach is a practical candidate when samples contain enough eligible events at the available concentration.", "The screening advantage must survive the assay's required sampling depth and controls. A very dilute sample or rare endpoint may need more acquisition than a minimum-time specification represents.", "Test the full screen recipe, from layout import through concentration-response analysis. Include cell loss, interference and missing-well cases. Favor the integrated workflow when it reduces hands-on review while preserving traceability and the required biological precision.Sources: F1. Configuration-based recommendation, not an independent speed ranking." ], [ "CytoFLEX S can suit a shared 96 well laboratory.FLEXIBLE ANALYZER USE", "CytoFLEX S offers multiple laser/filter configurations and CytExpert acquisition and analysis. Beckman describes an API for external control and integration with its liquid-handling platforms.", "Flexibility can be valuable when users bring different panels, but method changeover, training and maintenance still consume time. Optional automation and optical upgrades must be included in the proposed configuration.", "Assess it with the core lab's recurring panels and a realistic schedule of tube and plate work. Make 96-well throughput a measured acceptance criterion. Select it for a demonstrated workload fit rather than assuming a configurable analyzer automatically behaves like a dedicated screening workcell.Sources: F2. Manufacturer features and workflow recommendation." ], [ "Attune merits testing when useful sampling volume is a priority.VOLUME AND EVENT YIELD", "Attune's acoustic-focusing approach provides selectable high sample flow, and its autosampler methods specify analyzed volume and mixing. This gives a concrete basis for a demonstration with relatively dilute samples.", "More sampled liquid is useful only while coincidence, background, carryover and population recovery remain acceptable. Additional sample volume also increases the number of cells and reagents the assay must supply.", "Compare accepted events per microliter and per minute over the relevant concentration range. For scarce samples, include accessible volume and residual loss. Use the resulting data to choose an acquisition method before comparing end-to-end plate productivity.Sources: F4, F6. Mechanistic and workflow inference; proposed measurement." ] ], "data_kind": "source comparison and stated illustrative calculations" }, { "caption": "Flow cytometers for drug discovery screening — Notable Details", "rows": [ [ "The finding", "Technology and product evidence", "Trade-offs and controls", "What it means" ], [ "Use one challenge plate to compare the complete methods.DEMONSTRATION PLAN", "Include abundant and rare target populations, a dilution series, a bright interfering marker, aggregates and high–blank–low sequences. Distribute stable controls so acquisition-order effects can be detected.", "Keep biological preparation comparable while allowing each supplier to optimize a documented method. Artificially forcing identical flow settings can disadvantage a different sampling architecture without creating a fair scientific comparison.", "Compare final-gate counts, dim-population separation, carryover, rejected events, missed wells and review time. Set acceptable errors before the demonstration. Repeat on another day to test whether the method can be handed to the operators who will actually use it.Proposed matched-objective benchmark." ], [ "Cost the usable results and the labor behind them.PURCHASING DECISION", "The relevant quote includes the cytometer configuration, loader, software seats, integration, QC materials, cleaning supplies, service and training. A screening workflow may also need sample preparation automation and protected plate storage.", "Neither acquisition specifications nor list-price fragments establish total cost per accepted well. Instrument downtime and the time spent resolving bad gates can exceed the apparent saving from a faster plate cycle.", "Build the comparison around a stated annual workload and a defined endpoint. Ask suppliers to provide the configuration used in the demonstration and the support needed to maintain it. Record which future assays the proposed configuration can support, and which would require another purchase.Procurement framework; no price or service-performance ranking claimed." ] ], "data_kind": "source comparison and stated illustrative calculations" } ], "display_additions": {}, "content_sha256": "d1737db1aa19e875f5e22f09fb569286c67d21f265aba3d3da241f2c23872aaf" }